HCC recurrence in HCV-infected patients after liver transplantation: SiLVER Study reveals benefits of sirolimus in combination with CNIs - a post-hoc analysis by J.M. Werner et al.
ORIGINAL ARTICLE
HCC recurrence in HCV-infected patients after liver
transplantation: SiLVER Study reveals benefits of
sirolimus in combination with CNIs – a post-hoc
analysis
Jens M. Werner1 , Matthias Hornung1, Rubertha Krah1, Markus G€otz1, Andreas A. Schnitzbauer1,2,
Hans J. Schlitt1, Edward K. Geissler1,3 & the International SiLVER study group
1 Department of Surgery,
University Hospital Regensburg,
Regensburg, Germany
2 Department of Surgery,
University Hospital Frankfurt,
Frankfurt am Main, Germany
3 Division of Personalized Tumor




Jens M. Werner, Department of
Surgery, University Hospital
Regensburg, Franz-Josef-Strauss-Allee





Factors affecting outcomes in liver transplant (LTx) recipients with hepato-
cellular carcinoma (HCC) and hepatitis C viral (HCV) infection include the
choice of immunosuppression. Here, we analyzed the HCV+ subgroup of
patients from the randomized controlled, international SiLVER Study. We
performed a post hoc analysis of 166 HCV+ SiLVER Study patients regarding
HCC outcome after LTx. Control patients (group A: n = 88) received mTOR
inhibitor (mTORi)-free, calcineurin inhibitor (CNI)-based versus sirolimus-
based immunosuppression (group B: n = 78). We found no significant dif-
ference regarding HCV-RNA titers between group A and B. Since no effect in
group B could be due to variable sirolimus dosing, we split group B into
patients receiving sirolimus-based immunosuppression + CNIs for >50%
(B1; n = 44) or <50% (B2; n = 34) of the time. While there remained no dif-
ference in HCV-RNA titer between groups, HCC recurrence-free survival in
group B1 (81.8%) was markedly better versus both group A (62.7%;
P = 0.0136) and group B2 (64.7%; P = 0.0326); Interestingly, further sub-
group analysis revealed an increase (P = 0.0012) in liver enzyme values in
group B2. Taken together, in HCV-infected patients with HCC and LTx,
mTORi immunosuppression + CNIs yields excellent outcomes. Unexpect-
edly, higher levels of liver inflammation and poorer outcomes occur with
mTORi monotherapy in the HCV+ subgroup.
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Background
During the last two decades, hepatocellular carcinoma
(HCC) has become the fastest rising cause of cancer-re-
lated deaths and has contributed to the increase in pro-
portion of patients undergoing liver transplantation
(LTx) for HCC [1]. LTx is a preferred treatment option
since cirrhosis is often the underlying disease, and
therefore, organ replacement offers a potential simulta-
neous cure for two otherwise fatal diseases [2]. Even
with LTx, approximately one out of five recipients expe-
rience HCC recurrence post-transplantation, which is a
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leading cause of morbidity and mortality in these cases
[3,4]. Application of strict rules for selection of LTx
recipients with limited HCC (i.e., Milan criteria) reduce
the likelihood of post-LTx HCC recurrence [5,6]. In
addition, the use of immunosuppression with anti-can-
cer effects, namely mechanistic target of rapamycin inhi-
bitors (mTORi), has further improved the outlook for
certain patients, as demonstrated recently in the SiLVER
Study [7]. The SiLVER Study was a prospective-ran-
domized open-label multicenter international trial
investigating whether sirolimus-based immunosuppres-
sion improves the outcome in LTx recipients with
HCC. Results from this trial show that although flexible
incorporation of sirolimus into an immunosuppressive
regimen does not indefinitely improve long-term HCC
recurrence-free (RFS) and overall survival (OS), out-
comes are improved in the first 3–5 years after trans-
plantation, especially in patients with tumors within
Milan Criteria and on mTORi monotherapy [7].
Here, in the present analysis of HCV+ patients from
the SiLVER Study, we posed the question whether cer-
tain specific immunosuppressive regiments could other-
wise benefit this special subpopulation of patients. To
examine this question, we compared those patients that
received an mTORi-free, calcineurin inhibitor (CNI)–
based, immunosuppressive protocol (group A) to those
that received sirolimus (mTORi)-based immunosup-
pression with CNI for either more (group B1) or less




For the SiLVER Study, 525 LTx recipients were
recruited from 45 transplant centers in Europe (42),
Canada (2), and Australia (1) in a multicenter, random-
ized, open-labeled, parallel group trial (EudraCT: 2005-
005362-36; Clinicaltrials.gov: NCT00355862). The inclu-
sion criteria for eligible patients (>18 years old) were
histologically proven HCC before randomization and
signed written informed consent. The main exclusion
criteria were extrahepatic HCC manifestation and non-
HCC malignancies within the past 5 years. The first
patient was randomized in January 2006 with random-
ization completed in April 2009. All patients were fol-
lowed up for at a minimum of 5 years post-LTx, with
the last visit being conducted in March 2014.
Randomization
Patients were randomized into two groups. Group A
was maintained on a center-specific mTORi-free, gener-
ally CNI-based, immunosuppressive protocol. In group
B, sirolimus was incorporated into the regime (target
range, 4–10 ng/ml) after 4 to 6 weeks, either as a
monotherapy or as a combination therapy with non-
mTORi–based drugs. More details of the protocol are
published elsewhere [7,8].
Outcomes
As detailed in the original publication of the SiLVER
Study [7], the primary endpoint of RFS was defined as
HCC recurrence or patient death. Patients underwent a
standardized tumor-specific follow-up at every visit. In
the first year after LTx, all patients were followed up
after month 1, 3, 6, 9, and 12; thereafter, patients were
followed up every 6 months. OS was a secondary end-
point in the study.
Analysis
Within group A and B, 88 and 78 patients, respec-
tively, were HCV-RNA positive at the time of random-
ization. HCV recurrence was determined by HCV
viremia and elevated transaminases as per local cen-
ter’s practice/investigator discretion, in the absence of
other reasons for graft dysfunction. Furthermore, liver
inflammation was also assessed by measuring liver
transaminases. For this post hoc analysis, five patients
were excluded from group A due to mTORi applica-
tion for more than one visit. To investigate the effect
of mTORi monotherapy, group B was subdivided fur-
ther based on the number of visits where the patients
received mTORi in combination with CNIs. Based on
an initial per protocol definition, patients in group B1
(n = 44) received mTORi-based immunosuppression
with CNIs for more than 50% of the time, while
patients in group B2 (n = 34) for less than 50% of the
time. To confirm our observation, we calculated the
median time of mTORi-based immunosuppression
without CNIs (median 6 months, IQR 0–37.5 months)
in the whole group B. Based on this calculation, we
subdivided group B into B1 (n = 38) with mTORi-
based immunosuppression without CNIs < 6 months
and B2 (n = 40) with mTORi-based immunosuppres-
sion without CNIs ≥ 6 months.
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Statistics
GraphPad Prism 7.0b (GraphPad Software, Inc., La
Jolla, USA) was used for Chi-squared and Kruksall–
Wallis tests, as well as for survival analysis and generat-
ing plots. All authors had access to the study data and
critically reviewed and approved the final version of the
manuscript.
Results
The HCV-positive subset (n = 166) of the complete
SiLVER Study (n = 525) was analyzed to find a poten-
tial immunosuppressive regimen that might help to
reduce HCC recurrence after LTx in patients with
chronic HCV infection (Fig. 1). We compared those
patients that received an mTORi-free, CNI-based,
immunosuppressive protocol (control group A, n = 88)
to those that received mTORi-based immunosuppres-
sion (group B; n = 78). Within group A, five patients
were switched to mTORi for more than one visit and
were therefore excluded from our analysis, leaving 83
patients in this group and 161 patients in total.
First, we wanted to determine whether mTORi-based
immunosuppression had an effect on HCV replication,
as previously reported from in vitro studies [9]. This
analysis did not reveal any significant difference regard-
ing HCV-RNA titers between group A and B patients
(Figure S1). We then speculated that the lack of an
effect in group B could be due to variable sirolimus
dosing (e.g., early discontinuation or use mainly in
combination with CNIs). Therefore, we split group B
into patients receiving sirolimus-based immunosuppres-
sion with CNIs for either more than (group B1;
n = 44), or less than (group B2; n = 34) 50% of the
visits (Fig. 1).
A summary of the demographic data is given in
Table 1 for all 161 analyzed patients. Notably, most
patients were men (87.6%) and white (96.9%). The
median age was 56.4 years, and the median time on the
waiting list for LTx was 0.33 years. Overall, the three
groups were well balanced with regard to the baseline
demographic data. Pathological HCC specifics are also
summarized in Table 1. A total of 115 patients (71.4%)
were within Milan Criteria, whereas 46 patients (28.6%)
had tumors outside Milan Criteria; this is a similar dis-
tribution that was published for the whole group [7].
For most patients (76.4%), the number of lesions was 1
or 2, whereas 23.6% of patients had 3 lesions or more.
The maximum tumor size was < 3 cm for 56.5%, 3 to
5 cm for 37.9%, and greater than 5 cm for 5.6% of
patients. Overall, the treatment groups were well bal-
anced for HCC specifics. Regarding HCV characteristics,
92 patients (57.1%) had a genotype 1 and 35 (21.7%) a
genotype 3 infection, while 25 patients (15.5%) were
not tested for their respective genotype (Table 1). In
this pre-DAA treatment era, 14 patients (8.7%) received
IFNa and 71 patients (44.1%) were treated with
pegIFNa plus ribavirin before LTx, while 76 patients
(47.2%) remained treatment na€ıve.
While there remained no difference in the HCV-RNA
titer (Fig. 2) between the three groups (A, B1 or B2), it
was interesting to find that HCC RFS in group B1
(81.8%; n = 36) was substantially, and significantly,
Figure 1 Patient disposition.
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mTORi + CNI) P value
Patient’s demographics
Number of patients 83 44 34
Age at the time of consent, years
Median 55.1 57 58.4 0.21**
(Q1–Q3) 51.8–63.7 52.3–61.8 54.1–63.6
Gender
Male 69 (83.1%) 41 (93.2%) 31 (91.2%) 0.20*
Female 14 (16.9%) 3 (6.8%) 3 (8.2%)
Race
White 80 (96.4%) 43 (97.7%) 33 (97.1%) 0.80*
African 1 (1.2%) 1 (2.9%)
Asian 1 (1.2%) 1 (2.3%)
Arabic 1 (1.2%)
Time on waiting list, years
Median 0.46 0.24 0.3 0.21***
(Q1–Q3) 0.17–0.92 0.14–0.64 0.07–1.01
Patient’s HCC characteristics before LTx
Within Milan criteria
Based on radiology report at listing 61 (73.5%) 31 (70.5%) 23 (76.5%) 0.84*
Based on pathology report after LTx 58 (70.7%) 32 (72.7%) 19 (55.9%) 0.22*
Maximum tumor size
>5 cm 4 (4.8%) 2 (4.5%) 3 (8.8%) 0.63*
3-5 cm 28 (33.7%) 18 (40.9%) 15 (44.1%)
<3 cm 51 (61.4%) 24 (54.5%) 16 (47.1%)
Median tumor size in pathology report 2.5 3 3 0.96***
(Q1–Q3) 1.5–3.5 1.5–4 1–4
Number of tumors
1–2 62 (74.7%) 32 (72.7%) 29 (85.3%) 0.38*
>3 21 (25.3%) 12 (27.3%) 5 (14.7%)
Patient’s HCV characteristics before LTx
Genotype
1 46 (55.4%) 25 (56.8%) 21 (61.8%) 0.66*
2 1 (1.2%) 0 (0%) 2 (6.5%)
3 19 (22.9%) 11 (23.4%) 5 (16.1%)
4 3 (3.6%) 2 (4.3%) 0 (0%)
5a 1 (1.2%) 0 (0%) 0 (0%)
not tested 13 (15.7%) 6 (12.8%) 6 (19.4%)
Pretreatment
IFN alone 6 (7.2%) 3 (6.8%) 5 (14.7%) 0.72*
pegIFN + RBV 38 (45.8) 19 (43.2%) 14 (41.2%)
naive 39 (47%) 22 (50%) 15 (44.1%)
Patient’s Follow-up after LTx
Patients with acute rejection (AR) 24 (28.9%) 12 (27.3%) 11 (32.4%) 0.88*
Patients received treatment for AR 20 (83.3%) 9 (75.0%) 6 (54.5%) 0.19*
Increase in immunosuppression 7 (29.2%) 3 (25.0%) 1 (9.1%) 0.65*
Steroids pulse 14 (58.3%) 6 (50.0%) 5 (45.5%) 0.77*
CMV infection 9 (10.8%) 1 (2.3%) 2 (5.9%) 0.20*
HCV recurrence 52 (62.7%) 27 (61.4%) 27 (79.4%) 0.17*
HCV treatment
pegIFN + RBV 31 (37.3%) 19 (43.2%) 15 (44.1%) 0.95*
pegIFN 3 (3.6%) 1 (2.3%) 1 (2.9%)
RBV 1 (1.2%) 0 (0%) 0 (0%)
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better compared with both group A (62.7%; n = 52,
P = 0.0136) and group B2 (64.7%; n = 22, P = 0.0326)
patients at study end (5–8 year follow-up) (Fig. 3a);
similarly, the OS was better in group B1 (86.4%),
compared with either group A (65.1%; P = 0.0078) or
group B2 (67.6%; P = 0.0399) (Fig. 3b). The signifi-
cantly better outcome in terms of RFS and OS was con-
firmed when group B was subdivided according to the
Figure 2 Patient follow-up during the first 3 years after randomization. HCV-RNA viral titer. Statistic: median +/ IQR; nonparametric Kruskal–
Wallis test.






mTORi + CNI) P value
HCV treatment outcome
SVR 15 (42.9%) 12 (60%) 6 (37.5%) 0.61*
Unknown 3 (8.6%) 0 (0%) 3 (18.8%)
HCC recurrence 14 (16.9%) 5 (11.4%) 7 (20.6%) 0.53*
SVR, sustained virological response.
Statistic: *v2 test; **One-way ANOVA; ***Kruskal–Wallis test.
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median time of mTORi-based immunosuppression
without CNIs (Figure S2).
Looking specifically at parameters that are known to
have an impact on outcome in chronic HCV-infected
patients during the follow-up after LTx (Table 1), there
was no significant difference between the three groups
with respect to acute rejection (n = 47; 29.2%), CMV
infection (n = 12; 7.5%), HCV treatment (n = 71;
44.1%) or the number of patients that achieved a sus-
tained virological response after treatment (n = 33;
46.5%). Although there was a difference in the time to
HCC recurrence between group B1 and B2, this trend
(P = 0.10) did not reach statistical significance over the
time course (Figure S3). Likewise, there was no signifi-
cant difference in the frequency of patients that experi-
enced an HCC recurrence (n = 26; 16%) between the
three groups (Table 1). However, looking at the labora-
tory workup at 3 to 6 months following LTx, there was
a significant (P = 0.0012) increase in ALT values in
group B2 (111; 61.3–205.8 (Median; Q1–Q3)) compared
with group A (55; 33–93) and group B1 (58.5; 30–95.8).
Interestingly, this significant increase in ALT values in
group B2 persisted throughout the first three years after
LTx (Fig. 4).
Discussion
In this subgroup analysis of HCV-positive patients
within the SiLVER Study, we found an improved HCC
RFS and OS for patients that received mTORi-based
immunosuppression in combination with CNIs for
more than 50% of the visits (group B1), as compared
to patients that were on mTORi without CNIs for more
than 50% of the time (group B2) or on CNIs only
(group A). Remarkably, this higher RFS and OS in the
group B1 receiving CNIs interestingly contrasts with
results from the intention-to-treat SiLVER Study analy-
sis dataset [7], which showed a survival benefit
particularly for those patients receiving mTORi
monotherapy (like group B2 patients). Therefore, cau-
tion should be taken when broadly applying the inten-
tion-to-treat SiLVER Study conclusions to all LTx
recipients with HCC, since certain patient subgroups
may be better served by the application of mTORi in
combination with other treatments.
The question then becomes why the HCV subgroup
of patients appear to benefit from a combination of
mTORi with CNIs. We hypothesized that too little
immunosuppression with mTORi monotherapy could
possibly be related to increased liver transaminases,
which might lead to serious morbidity and poorer out-
comes in this HCV-infected patient population [10,11].
Indeed, we present data that suggest patients on CNIs
plus mTORi had lower liver transaminases than mTORi
monotherapy patients. Therefore, we suggest that in
HCV-infected patients with HCC, CNIs help to keep
inflammation under control, but do not interfere with
the anti-tumor effects of mTORi. A balance between
anti-tumor activities and reduced liver inflammation
could be the reason for the excellent long-term out-
comes in this subgroup of patients on combined
mTORi/CNI therapy [12]. However, the reasons why
the HCV+ patients on CNIs plus mTORi had better
outcomes are complex and might also be attributed to
limitations of this secondary analysis that need to be
considered. First, the SiLVER Study was not designed or
powered to explore efficacy of CNIs alone vs. CNIs plus
mTORi vs. mTORi monotherapy. Secondly, the retro-
spective nature of our post hoc analysis and the limited
number of patients need to be emphasized. Further-
more, in the pre-DAA era of the SiLVER Study con-
duct, treatment regimens for HCV infection varied
widely and were not controlled in the study protocol,
so we do not know how this may have impacted out-
comes, especially in an internationally conducted trial.
Besides, measuring of HCV-related parameters such as
Figure 4 Patient follow-up during the first 3 years after randomization. ALT values in U/L. Statistic: median +/ IQR; nonparametric Kruskal–
Wallis test.
6 Transplant International 2020;
ª 2020 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT
Werner et al.
viral titer was not centrally performed, leaving our
knowledge of the HCV status of patients in question.
We must also recognize that besides strictly controlling
for the presence of mTORi use in the two study arms,
immunosuppressive regimens were largely left to the
discretion of the investigators, requiring here that we
design post hoc groups of patients on regimens within
certain selected parameters for this analysis. Further-
more, rejection rates and subsequent adjustments of the
immunosuppression such as steroid pulses or other
confounding factors cannot be ruled out as contributing
factors [13]. While we acknowledge these limitations,
the SiLVER Study is nonetheless the largest prospective
randomized controlled trial of LTx patients with HCC,
so no comparable HCV study cohort exists to examine
the questions we posed this analysis.
While these results from HCV-infected patients in the
SiLVER Study are interesting, it is important to consider
that treatment for HCV infection has dramatically chan-
ged since this trial was performed, with the advent of
DAA therapy [14-16]. Interestingly, although treatment
for HCV has now been revolutionized by successful DAA
treatments, we propose that our findings could provide
important insight into new options for optimizing out-
comes in those patients with HCC receiving a LTx. We
propose that since our data indicate that reducing inflam-
mation benefits these patients, elimination of the virus by
DAAs will also eliminate the probable cause of inflamma-
tion. Therefore, an important hypothesis coming from
our current study is that combining DAAs with mTORi
monotherapy in this special scenario could substantially
improve long-term outcomes. That benefit could be real-
ized in situations where HCV is eliminated before LTx, or
when it is necessary to treat with DAAs after LTx. While
this hypothesis predicts that mTORi monotherapy would
be particularly effective today in the DAA therapy era, the
concept will need to be proven in a randomized con-
trolled trial.
In summary, HCV-infected patients in the pre-DAA
(SiLVER Study) therapy era with HCC and a LTx bene-
fited from mTORi immunosuppression when used in
combination with limited CNIs to reduce virally related
inflammation, yielding excellent survival outcomes.
While higher levels of liver inflammation and poorer
outcomes were observed in the mTORi monotherapy
patients of the SiLVER Study, we suggest that reduced
viral-associated inflammation now possible in the era of
DAA HCV treatment might prove in future clinical tri-
als to optimize outcomes in this patient subpopulation
by combining synergistically with the anti-cancer activi-
ties of mTORi monotherapy.
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Figure S1. Patient follow-up during the first 2 years
after randomization. HCV RNA viral titer. Statistic:
Median +/ IQR; nonparametric Kruskal–Wallis test.
Figure S2. Patient outcome. (A) RFS and (B) OS.
Statistic: Gehan-Breslow-Wilcoxon test.
Figure S3. Patient outcome. Time to HCC recur-
rence. Statistic: Gehan-Breslow-Wilcoxon test.
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